Home > Healthcare > Drug Device Combination > Therapeutic Systems > Flowable Hemostats Market

Flowable Hemostats Market Trends

Report ID: GMI9238
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Flowable Hemostats Market Trends

Increasing incidence of accidents and trauma cases is a significant driver of the market. For instance, as per the American Association for the Surgery of Trauma, in the U.S., injury accounts for over 150,000 deaths and over 3 million non-fatal injuries per year. Around the world, injury is responsible for more than 5 million deaths per year.
Accidents, including those from vehicular crashes, industrial mishaps, and sports injuries, often result in severe bleeding that requires immediate and effective hemostatic treatment to control.
Flowable hemostats, with their ability to stop bleeding quickly and efficiently, play a crucial role in managing these cases.
Thus, as the number of accidents and trauma cases continues to rise globally, especially in developing regions with expanding industrial and transportation sectors, the demand for novel surgical hemostats is expected to increase significantly, thereby driving the growth of market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Flowable hemostats industry size recorded USD 723.8 million in 2023 and will exhibit a 5.7% CAGR between 2024 and 2032 due to increasing surgical procedures, the rising prevalence of chronic diseases and traumatic injuries and technological advancements.

The orthopedic surgery segment registered 18.6% flowable hemostats industry share in 2023, driven by rising prevalence of orthopedic conditions, advancements in surgical techniques and the development of specialized hemostatic products.

North America flowable hemostats industry will record 5.4% CAGR up to 2032, owing to advanced healthcare infrastructure, high prevalence rates of chronic diseases requiring surgical interventions, and significant investments in research and development.

Major players operating in the flowable hemostats industry are 3D Matrix Medical Technology, Aegis Lifesciences Private Limited, Baxter International Inc., CR Bard Inc. (Becton, Dickinson, and Company), Ethicon, Inc. (Johnson & Johnson), Ferrosan Medical Devices A/S, Pfizer, Inc., and Teleflex Incorporated are among others.